
As Medical Advisor, Obesity and MASH, you will lead affiliate medical strategy and scientific excellence in obesity and metabolic dysfunction-associated steatohepatitis (MASH) in Korea. You will guide priority medical projects from planning to launch readiness. You will also turn expert insight and emerging evidence into clear recommendations that shape medical and business strategy. Working closely with Regional Medical Advisors, you will help make sure scientific exchange is balanced, compliant and useful to the people who treat obesity and MASH.
You bring the medical and scientific depth to lead strategy, and the communication skills to make complex data clear and balanced. You will need:
Useful, but not essential:
You will lead the medical strategy for obesity and MASH in Korea, from early planning through launch and beyond, and make sure every activity is built on sound science and strong ethical standards.
You will join the Medical Affairs department at Novo Nordisk Korea in Seoul, part of International Operations. The team leads scientific communication and medical strategy for the affiliate and works in a fast-paced environment where high medical standards and close collaboration go hand in hand.
Your closest partners will be the field-based Regional Medical Advisors, who you will support with medical guidance and scientific preparedness. You will also work with cross-functional colleagues across the affiliate and with real-world evidence teams. Externally, you will build relationships with priority national and regional experts in obesity and MASH.
These relationships connect what you hear in the field with the decisions made inside Novo Nordisk – helping the team move from insight to action with clarity and speed.
You will take ownership of a therapy area where science is moving fast and the need is real. Your expertise will be valued, and your voice will shape how medical strategy is set and delivered in Korea. Leading launch preparation, evidence generation and external engagement gives you the opportunity to broaden your experience and build new skills alongside colleagues across functions.
You will be supported to perform at your best and trusted to make decisions, with a clear expectation that care for people and integrity in every scientific exchange are never compromised.
Your impact begins today. If you are ready to shape medical strategy and scientific exchange in obesity and MASH in Korea, apply for the Medical Advisor, Obesity and MASH role

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.
Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:
https://www.novonordisk.com/contact-us/find-local-information.html
For other customer complaints, please contact us here:
https://www.novonordisk.com/contact-us.html
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.
Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html